The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

(2009) J. A. Burger et al.   BLOOD

A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy

(2009) W. W.L. Choi et al.   CLINICAL CANCER RESEARCH

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP

(2009) Heidi Nyman et al.   MODERN PATHOLOGY

SPARC: a matricellular regulator of tumorigenesis

(2009) Shanna A. Arnold et al.   Journal of Cell Communication and Signaling

Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling

(2008) R. J. Byers et al.   BLOOD

General morphological and biological features of neoplasms: integration of molecular findings

(2008) S J Diaz-Cano   HISTOPATHOLOGY

The Copper Binding Domain of SPARC Mediates Cell Survivalin Vitrovia Interaction with Integrin β1 and Activation of Integrin-linked Kinase

(2008) Matt S. Weaver et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of CD68 tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis

(2008) Sverker Hasselblom et al.   PATHOLOGY INTERNATIONAL

LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab

(2007) Yasodha Natkunam et al.   JOURNAL OF CLINICAL ONCOLOGY